Ouoba K, Lehmann H, Pabst J-Y, Semde R
Laboratoire du développement du médicament (LADME), centre de formation, de recherche et d'expertises en sciences du médicament (CEA-CFOREM), école doctorale sciences et santé (ED2S), université Joseph KI-ZERBO, 03 BP 7021 Ouagadougou, Burkina Faso; EA 7307, Centre d'études internationales et européennes (CEIE), faculté de pharmacie, université de Strasbourg, 74, route du Rhin, 67400 Illkirch, France.
EA 4487, Centre de recherches en droit et perspectives du droit, faculté de pharmacie, université de Lille, rue du Professeur-Laguesse, BP 53, 59006 Lille, France.
Ann Pharm Fr. 2022 Sep;80(5):635-645. doi: 10.1016/j.pharma.2021.11.007. Epub 2021 Dec 9.
After the initial stage of the pharmacovigilance process for medicines from traditional pharmacopoeias - which concerns the identification of the risks associated with their use - the risk assessment should now be approached. The latter makes it possible to detect potential signals early and to take preventive measures. We sought to understand, from a review of the literature, the steps and methods of risk assessment relating to traditional medicines, as well as the prevention strategies applied to them. All of the work carried out on the subject has shown that the steps and methods for assessing and preventing drug risks are the same for both conventional and traditional medicines. Risk assessment includes analysis of the quality of individual notifications, assessment of causality, detection and evaluation of signals. The World Health Organization method is the most widely used for causality assessment internationally, while disproportionality measures are the most applied for signal detection. Regarding prevention, risk communication is the main strategy for the risks associated with traditional medicines. This review suggests the involvement of traditional medicine practitioners both in the notification system and in the communication strategy on the risks associated with their products.
在传统药典药物的药物警戒流程初始阶段(该阶段涉及识别与其使用相关的风险)之后,现在应该进行风险评估。后者能够早期检测潜在信号并采取预防措施。我们试图通过文献综述了解与传统药物相关的风险评估步骤和方法,以及应用于它们的预防策略。关于该主题开展的所有工作表明,评估和预防药物风险的步骤和方法对于传统药物和常规药物而言是相同的。风险评估包括对个体报告质量的分析、因果关系评估、信号检测和评估。世界卫生组织的方法在国际上是因果关系评估中使用最广泛的,而不成比例性措施在信号检测中应用最为普遍。关于预防,风险沟通是与传统药物相关风险的主要策略。本综述建议传统医学从业者参与报告系统以及与其产品相关风险的沟通策略。